Humam Akbik, MD
Interventional Pain Medicine · Fairfield, OHNPI 1821041674
Payments from drug & device makers
Across 1,138 payments — averaging $102.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$30K
- Abbott$20K
- Boston Scientific$17K
- Stimwave Technologies Incorporated$16K
- Vertos Medical, Inc.$9K
- Orthofix Medical, Inc.$5K
- plus $20K from 54 others
Across 3 payments — averaging $897.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$3K
- Saluda Medical Americas, Inc.$51
What the payments were for
- Consulting fees$22,03519%
- Speaking & faculty fees$50,40443%
- Travel & lodging$11,35110%
- Food & beverage$32,22028%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- StimQ Receiver Stimulator Kit Channel A US w Receiver$15,480
- StimQ Freedom 8A Receiver Kit Channel A US w Receiver$15,480
- Freedom 4A Receiver Kit Channel A US w Receiver$15,480
- Freedom 8A Receiver Kit Channel A US w Receiver$15,480
- StimQ Freedom-4A Receiver Kit Channel A US w/ Receiver$13,756
- mild Device Kit$10,914
- PROCLAIM$10,767
- INTELLIS$9,988
- KYPHON Balloon Kyphoplasty$8,640
- SPECTRA WAVEWRITER$7,952
- ADAPTIVESTIM$4,990
- FIREBIRD SFS$4,500
- Neuromodulation Dspsbls and Accs$3,400
- Superion Indirect Decompression System$3,129
- INTELLIS ADAPTIVESTIM$3,100
- Evoke SCS$2,071
- StimQ Freedom 4A Receiver Kit Channel A US Receiver$1,724
- GENERAL PAIN MANAGEMENT$1,600
- GENERAL - THERAPIES$1,252
- Lucemyra/Lofexidine$1,000
How this compares
$116,560 in reported general payments places this provider in the 95th percentile of 67 interventional pain medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucyntaTapentadol Hcl | 17 | $19,167 |
| Xtampza ErOxycodone Myristate | 24 | $15,591 |
| LinzessLinaclotide | 23 | $12,651 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 329 | $8,273 |
| BelbucaBuprenorphine Hcl | 11 | $7,747 |
| Buprenorphine | 33 | $7,660 |
| MovantikNaloxegol Oxalate | 15 | $5,935 |
| Lidocaine | 40 | $3,918 |
| Pregabalin | 131 | $3,598 |
| Morphine Sulfate | 131 | $3,559 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 146 | $2,952 |
| Gabapentin | 221 | $2,890 |
| Fentanyl | 14 | $1,094 |
| Tizanidine Hcl | 115 | $1,089 |
| Cyclobenzaprine Hcl | 81 | $1,037 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er, Belbuca | $341 | $42,50552 claims |
| AbbVieLinzess | $1,065 | $12,65123 claims |
| Redhill Biopharma Inc.Movantik | $85 | $5,93515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 67 interventional pain medicine providers in Ohio.
Other interventional pain medicine in Fairfield
- Gladstone McDowellColumbus$701K
- Amol SoinDayton$184K
- Sara NashiCincinnati$140K
- Jaudat MahmoodKent$97K
- David WalegaColumbus$75K
- Jayesh VallabhColumbus$73K
- Omar AliSpringfield$67K
- Dustin ReynoldsWesterville$62K
- Mark MalinowskiChillicothe$57K
- Daniel VerrillKettering$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.